Heart Failure Clinical Trials in The Bronx, New York

7 studies are recruiting for heart failure in The Bronx, New York right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Investigation of the BrioVAD System for the Treatment of Left Ventricular Heart Failure

   The goal of this study is to evaluate the safety and efficacy of the BrioVAD System by demonstrating non-inferiority to the HeartMate 3 Left Ventricular Assist System when used for the treatment of advanced, refractory, left ventricular heart failure.

   Stage

   Not phased

   Ages

   18 to 100

   Site

   Montefiore Medical Center, The Bronx, New York

   Locations

   47 in total

   Run by

   BrioHealth Solutions, Inc.

   See if you can join NCT06310031 on ClinicalTrials.gov

2. Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)

   This study aims to compare the efficacy of vericiguat versus placebo on change in n-terminal pro-brain natriuretic peptide (NTproBNP) from baseline to Week 16 of the Base Period. The primary hypothesis is that vericiguat is superior to placebo in reducing NT-proBNP at Week 16 of the Base Period.

   Stage

   Phase 2

   Ages

   0 to 17

   Site

   The Children's Hospital at Montefiore ( Site 0030), The Bronx, New York

   Locations

   109 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT05714085 on ClinicalTrials.gov

3. Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction

   The purpose of this study is to find out if the investigational drug called omecamtiv mecarbil can reduce the risk of the effects of heart failure, like hospitalization, transplantation, or death in patients with heart failure and severely reduced ejection fraction.

   Stage

   Phase 3

   Ages

   18 to 85

   Site

   Montefiore Medical Center (Moses Campus), The Bronx, New York

   Locations

   205 in total

   Run by

   Cytokinetics

   See if you can join NCT06736574 on ClinicalTrials.gov

4. A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure

   This study is open to adults aged 18 or above legal age with heart failure. People can join the study if they have heart failure symptoms and a left ventricular ejection fraction (LVEF) of 40% or more. The purpose of this study is to find out whether vicadrostat (BI 690517) in combination with empa…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Cardiac Care and Vascular Medicine, PLLC, The Bronx, New York

   Locations

   652 in total

   Run by

   Boehringer Ingelheim

   See if you can join NCT06424288 on ClinicalTrials.gov

5. Cardiovascular Multimodality Imaging Study

   Determining the etiology of cardiomyopathy is of high clinical importance for optimal treatment strategy and prediction of prognosis. There is increased risk for cardiovascular disease and higher propensity for cardiovascular related mortality among Black and non-Hispanic White patients. Recently, …

   Stage

   Not phased

   Ages

   18 and older

   Site

   Montefiore Health System, The Bronx, New York

   Run by

   Montefiore Medical Center

   See if you can join NCT06610019 on ClinicalTrials.gov

6. Trial to Evaluate Safety And Effectiveness of Mechanical Circulatory Support in Patients With Advancing Heart Failure

   The purpose of TEAM-HF IDE clinical trial is to evaluate safety and effectiveness of the HeartMate 3 LVAS compared to guideline directed medical therapy (GDMT) in a population of ambulatory advanced heart failure patients who are not dependent on intravenous inotrope.

   Stage

   Not phased

   Ages

   18 and older

   Site

   Montefiore Medical Center - Moses Campus, The Bronx, New York

   Locations

   68 in total

   Run by

   Abbott Medical Devices

   See if you can join NCT06526195 on ClinicalTrials.gov

7. Sotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease

   Powerful new drugs that can prevent or delay end stage kidney disease (ESKD) - so called sodium-glucose cotransporter-2 inhibitors (SGLT2i) - are now available for patients with type 2 diabetes. Whether these drugs have similar effects in patients with type 1 diabetes (T1D) remains unknown because …

   Stage

   Phase 3

   Ages

   18 to 75

   Site

   Albert Einstein College of Medicine / Montefiore Medical Center, The Bronx, New York

   Locations

   19 in total

   Run by

   Alessandro Doria

   See if you can join NCT06217302 on ClinicalTrials.gov